

Study reveals mixed results for common stimulant in treating binge eating disorder

February 6, 2025

<https://chadd.org/adhd-in-the-news/study-reveals-mixed-results-for-common-stimulant-in-treating-binge-eating-disorder/>

(Excerpt — the source limited full access.)

Lisdexamfetamine, marketed as Vyvanse, first received approval from the Food and Drug Administration for the treatment of ADHD, "but its ability to also reduce the frequency of binge eating episodes led to its approval for binge eating disorder," said Morgan James, assistant professor of psychiatry, member of the Rutgers Addiction Research Center at the Brain Health Institute, and senior author of the study.

[This CHADD "ADHD in the News" entry carries only the above excerpt and links out to the full article on News-Medical.net, February 3, 2025.]